Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering

    Question

    Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering

    Direct answer

    Clinical-stage vaccine developer Vaxcyte announced pricing terms for a $1.0 billion aggregate capital raise. The package includes 7.4 million common shares at $64.00 per share, pre-funded warrants, and $500 million of 1.50% convertible senior notes due in 2032. The capital injection bolsters the balance sheet for pipeline execution but introduces near-term stock dilution and delta hedging dynamics associated with the new convertible paper.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1-0b-concurrent-common-stock-and-convertible-notes-offering-cdd9ae

    EQUITY
    Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering
    Clinical-stage vaccine developer Vaxcyte announced pricing terms for a $1.0 billion aggregate capital raise. The package includes 7.4 million common shares at $64.00 per share, pre-funded warrants, and $500 million of 1.50% convertible senior notes due in 2032. The capital injection bolsters the balance sheet for pipeline execution but introduces near-term stock dilution and delta hedging dynamics associated with the new convertible paper.
    PCVX
    Impact
    72
    OCT 7
    SIG
    92%
    PCVX
    Vaxcyte Prices $1.0B Concurrent Common Stock and Convertible Notes Offering
    Clinical-stage vaccine developer Vaxcyte announced pricing terms for a $1.0 billion aggregate capital raise. The package includes 7.4 million common shares at $64.00 per share, pre-funded warrants, and $500 million of 1.50% convertible senior notes due in 2032. The capital injection bolsters the balance sheet for pipeline execution but introduces near-term stock dilution and delta hedging dynamics associated with the new convertible paper.
    → Equity issuance at $64.00 per share sets an immediate liquidity benchmark and dilutes existing equity while convertible hedging may pressure spot shares.
    Impact
    Clinical-stage vaccine developer Vaxcyte announced pricing terms for a $1.0 billion aggregate capital raise. The package includes 7.4 million common shares at $64.00 per share, pre-funded warrants, and $500 million of 1.50% convertible senior notes due in 2032. The capital injection bolsters the balance sheet for pipeline execution but introduces near-term stock dilution and delta hedging dynamics associated with the new convertible paper.
    Affected
    PCVX
    Transmission
    Equity issuance at $64.00 per share sets an immediate liquidity benchmark and dilutes existing equity while convertible hedging may pressure spot shares.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible note arbitrage delta sellingDown1-5dVaxcyte announced pricing of 7.4 million shares at $64.00 and $500 million of 1.50% convertible senior notes.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXDownagreed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month